Introduction {#section1-2049936119868028}
============

Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite there being 10--15 million people infected worldwide.^[@bibr1-2049936119868028],[@bibr2-2049936119868028]^ As in HIV infection, chronicity uniformly occurs following acute HTLV-1 acquisition and there are no self-limited infections. However, less than 10% of HTLV-1 carriers may develop lifelong clinical manifestations, including two life-threatening illnesses, namely a subacute invalidating myelopathy known as tropical spastic paraparesis (TSP)^[@bibr3-2049936119868028]^ and an acute T-cell leukemia/lymphoma (ATLL).^[@bibr4-2049936119868028]^

HTLV-1 is efficiently transmitted perinatally (breastfeeding), sexually (more from male to female) and parenterally (transfusions, injection drug use and transplants).^[@bibr2-2049936119868028]^ The diagnosis is based on the demonstration of specific serum HTLV-1 antibodies. A high HTLV-1 proviral load predicts the risk of disease development^[@bibr5-2049936119868028]^ and sexual transmission.^[@bibr6-2049936119868028]^ To date there is neither prophylactic vaccine nor effective antiviral therapy.^[@bibr7-2049936119868028]^

Spain is one of the world leading countries performing solid organ transplants. The annual figure is steadily rising, and is currently nearly 5300 transplants per year. To date, more than 110,000 individuals have benefited from organ donations. More than 60% are kidney transplants, with liver being the second most frequent allograft. Heart, lung and pancreas are transplanted less frequently. On the other hand, of the nearly 47 million people currently living in Spain, around 4.5 million are foreigners. In addition, the country is a frequent destination for tourists, with 75 million visitors during 2016, more than 10% from HTLV-1 endemic regions.^[@bibr8-2049936119868028]^

Rapid-onset subacute myelopathy and T lymphomas associated with HTLV-1 infection have both been reported following solid organ transplantation. At least three different scenarios have been described for HTLV-1 acquisition and disease in the transplantation setting, including infection from the organ donor, contaminated blood transfusions during surgery, and baseline carriage of HTLV-1 by the recipient.^[@bibr9-2049936119868028],[@bibr10-2049936119868028]^ It seems that the immunosuppression used to avoid organ rejection (e.g. corticoids, tacrolimus, cyclosporine, mycophenolate, etc.) plays a major role in frequent and rapid-onset disease development in this population, particularly for HTLV-1 associated myelopathy (HAM).^[@bibr9-2049936119868028],[@bibr10-2049936119868028]^

Case reports {#section2-2049936119868028}
============

Patient 1 {#section3-2049936119868028}
---------

During 2015 a 54-year-old woman underwent kidney transplantation in Spain. She was a white native Spaniard and denied any risk factors for HTLV-1 infection. To date, HTLV testing of blood and tissues in Spain is only recommended for 'donors that came from or live in highly endemic regions, or have either sex partners or parents from those regions'.^[@bibr11-2049936119868028]^ However, many transplantation centers do HTLV screening in all donor-recipients when possible. In this case, results of the donor HTLV testing are received after surgery, informing of reactivity for HTLV antibodies using a commercial enzyme immunoassay. No organs other than the two kidneys were transplanted from the same donor.

Positivity for HTLV-1 in the first kidney recipient was confirmed thereafter using immunoblot. Soon after this became known she was informed and antiretroviral therapy with zidovudine, lamivudine plus raltegravir was introduced within the first week following transplantation. Antiretrovirals were used for at least 18 months. In a retrospective interview of the deceased donor's relatives, it became apparent that he most likely had acquired HTLV-1 from a Brazilian heterosexual partner.

Eight months later the recipient developed difficulty walking, along with unsteady gait, followed by progressive lower extremity weakness, all suggestive of HAM/TSP.^[@bibr12-2049936119868028]^ Her HTLV-1 proviral load had been high in sequential longitudinal samples collected soon after transplantation, in the range of 320--350 HTLV-1 DNA copies per 10,000 peripheral blood mononuclear cells/ml. At the time of presentation of the initial neurological symptoms, the proviral load in the cerebrospinal fluid was also very high (2340 HTLV-1 DNA copies per 10,000 mononuclear cells/ml).

Patient 2 {#section4-2049936119868028}
---------

A 65-year-old male was the second kidney transplant recipient from the same infected donor. Like the other recipient, he was a white native Spaniard who denied any risk factor for HTLV-1 infection. He also became infected with HTLV-1 after transplantation but to date, 3 years later, has not developed any disease. He received antiretroviral drugs, including zidovudine, lamivudine plus raltegravir during the first 2 months following transplantation. It should be highlighted that immunosuppressive therapy (mycophenolate and tacrolimus) dosing had to be reduced from the second month due to hematological toxicity. Finally, rejection of the allograft forced its removal 8 months following transplantation. The patient is no longer undergoing immunosuppressant treatment and is currently undergoing hemodialysis. His proviral load has always been low, in the range of 25 HTLV-1 DNA copies per 10,000 peripheral blood mononuclear cells/ml.

Discussion {#section5-2049936119868028}
==========

Similar cases of HAM/TSP shortly after transplantation have been reported in the literature ([Table 1](#table1-2049936119868028){ref-type="table"}).^[@bibr13-2049936119868028][@bibr14-2049936119868028][@bibr15-2049936119868028][@bibr16-2049936119868028][@bibr17-2049936119868028][@bibr18-2049936119868028][@bibr19-2049936119868028][@bibr20-2049936119868028][@bibr21-2049936119868028][@bibr22-2049936119868028][@bibr23-2049936119868028][@bibr24-2049936119868028]--[@bibr25-2049936119868028]^ Myelopathy was originally reported in a heart transplant recipient in France following HTLV-1 acquisition from contaminated blood transfusions during the surgery.^[@bibr13-2049936119868028]^ In Spain, two kidney recipients and one liver transplant recipient who received organs from a single deceased HTLV-1 donor developed HAM/TSP within 2 years.^[@bibr16-2049936119868028]^ More recently, in the USA two kidney transplant recipients from separate infected donors developed HAM/TSP.^[@bibr19-2049936119868028],[@bibr20-2049936119868028]^

###### 

Reports of HTLV-1 associated diseases in solid organ transplant recipients.HAM/TSP developed in recipients negative for HTLV-1 who received organs from infected donors or, more occasionally, contaminated blood transfusions during surgery. In contrast, most recipients who developed ATLL were HTLV-1 before transplantation and immunosuppression.

![](10.1177_2049936119868028-table1)

                                                                        Country   Year   Age (years)   Gender   Organ    Interval     Reference
  --------------------------------------------------------------------- --------- ------ ------------- -------- -------- ------------ ------------------------------------------------
  HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP)                                                                 
  1                                                                     France    1990   41            Male     Heart    5 months     Gout et al.^[@bibr13-2049936119868028]^
  2                                                                     Japan     1992   32            Male     Kidney   11 months    Kuroda et al.^[@bibr14-2049936119868028]^
  3                                                                     Japan     2000   50            Male     Kidney   4 years      Nakatsuji et al.^[@bibr15-2049936119868028]^
  4                                                                     Spain     2003   44            Female   Liver    18 months    Toro et al.^[@bibr16-2049936119868028]^
  5                                                                     Spain     2003   54            Female   Kidney   \<3 months   Toro et al.^[@bibr16-2049936119868028]^
  6                                                                     Spain     2003   57            Male     Kidney   20 months    Toro et al.^[@bibr16-2049936119868028]^
  7                                                                     Japan     2008   58            Male     Liver    20 months    Soyama et al.^[@bibr17-2049936119868028]^
  8                                                                     Japan     2010   51            Male     Kidney   10 months    Inose et al.^[@bibr18-2049936119868028]^
  9                                                                     USA       2014   56            Male     Kidney   5 months     Ramanan et al.^[@bibr19-2049936119868028]^
  10                                                                    USA       2015   59            Female   Kidney   8 years      Younger^[@bibr20-2049936119868028]^
  11                                                                    Germany   2016   46            Female   Kidney   4 years      Gövert et al.^[@bibr21-2049936119868028]^
  12                                                                    Japan     2015   38            Female   Kidney   2 months     Nagamine et al.^[@bibr22-2049936119868028]^
  13                                                                    Japan     2016   42            Female   Kidney   3 years      Tajima et al.^[@bibr23-2049936119868028]^
  14                                                                    Japan     2016   65            Male     Kidney   8 months     Tajima et al.^[@bibr23-2049936119868028]^
  15                                                                    Japan     2016   ?             ?        Liver    15 months    Yoshizumi et al.^[@bibr24-2049936119868028]^
  16                                                                    Japan     2016   ?             ?        Liver    46 months    Yoshizumi et al.^[@bibr24-2049936119868028]^
  17                                                                    Ecuador   2016   40            Male     Kidney   2 years      Montesdeoca et al.^[@bibr25-2049936119868028]^
  18                                                                    Spain     2016   54            Female   Kidney   8 months     Current case
  Adult T-cell leukemia/lymphoma (ATLL)                                                                                               
  1                                                                     Canada    1989   58            Female   Kidney   11 years     Zanke et al.^[@bibr26-2049936119868028]^
  2                                                                     UK        1995   ?             Male     Kidney   ?            Jenks et al.^[@bibr27-2049936119868028]^
  3                                                                     Japan     2001   32            Male     Kidney   5 months     Hoshida et al.^[@bibr28-2049936119868028]^
  4                                                                     Japan     2001   32            Male     Kidney   11 months    Hoshida et al.^[@bibr28-2049936119868028]^
  5                                                                     Japan     2001   43            Male     Kidney   4 years      Hoshida et al.^[@bibr28-2049936119868028]^
  6                                                                     Japan     2001   56            Male     Kidney   18 months    Hoshida et al.^[@bibr28-2049936119868028]^
  7                                                                     Japan     2001   47            Female   Kidney   \<3 months   Hoshida et al.^[@bibr28-2049936119868028]^
  8                                                                     Japan     2006   39            Female   Liver    6 months     Kawano et al.^[@bibr29-2049936119868028]^
  9                                                                     Japan     2006   67            Male     Liver    9 months     Kawano et al.^[@bibr29-2049936119868028]^
  10                                                                    Japan     2006   45            Male     Liver    25 months    Kawano et al.^[@bibr29-2049936119868028]^
  11                                                                    Germany   2008   59            Male     Liver    2 years      Glowacka et al.^[@bibr30-2049936119868028]^
  12                                                                    Germany   2009   28            Male     Kidney   3 years      Glowacka et al.^[@bibr30-2049936119868028]^
  13                                                                    Japan     2016   39            Female   Liver    181 days     Yoshizumi et al.^[@bibr24-2049936119868028]^
  14                                                                    Japan     2016   45            Male     Liver    291 days     Yoshizumi et al.^[@bibr24-2049936119868028]^
  15                                                                    Japan     2016   67            Male     Liver    257 days     Yoshizumi et al.^[@bibr24-2049936119868028]^
  16                                                                    Japan     2016   48            Male     Liver    823 days     Yoshizumi et al.^[@bibr24-2049936119868028]^
  17                                                                    Japan     2016   59            Female   Liver    1315 days    Yoshizumi et al.^[@bibr24-2049936119868028]^

In Japan, where HTLV-1 is endemic, cases of HAM/TSP have been reported following either kidney or liver transplants.^[@bibr14-2049936119868028],[@bibr15-2049936119868028],[@bibr17-2049936119868028],[@bibr22-2049936119868028][@bibr23-2049936119868028]--[@bibr24-2049936119868028]^ More interesting, however, is the diagnosis of ATLL shortly following solid organ transplants, mostly among native Japanese recipients already infected with HTLV--1.^[@bibr28-2049936119868028],[@bibr29-2049936119868028]^ Similar cases have been reported in other places.^[@bibr26-2049936119868028],[@bibr27-2049936119868028]^ This is somewhat unique since most post-transplant lymphoproliferative disorders are of B lymphocytes and linked to Epstein--Barr virus infection. Anecdotally, in Germany, transplanted kidneys and a liver resulted in primary cutaneous T-cell lymphoma in at least two patients infected from a single HTLV-1 donor.^[@bibr30-2049936119868028]^ [Table 1](#table1-2049936119868028){ref-type="table"} summarizes the major features of ATLL cases reported so far following solid organ transplantation.

These findings call into question the current view that anti-HTLV screening of donated organs is not needed or is only recommended when there is suspicion. This opinion is based on the assumption that HTLV-1 associated diseases will develop only in a small proportion of carriers and that progression to disease is slow compared with the average lifespan of humans and therefore poses no major threats to public health.^[@bibr31-2049936119868028]^ We postulate that in the transplant setting the very high risk of transmission and the high rate along with the rapidity of developing HTLV-1 disease is the result of immunosuppressive therapy. Interestingly, it seems to be a divergent predominant clinical manifestation depending on whether the allograft derives from an HTLV-1 infected donor or it is the recipient who actually carries the virus ([Figure 1](#fig1-2049936119868028){ref-type="fig"}). When the recipient is already infected, transplantation might lead more frequently to ATLL, whereas when HTLV-1 is acquired from the donor, the recipient's greater risk is for HAM/TSP.

![Model for HTLV-1 disease development in transplant recipients.](10.1177_2049936119868028-fig1){#fig1-2049936119868028}

In a recent large retrospective study conducted in Japan including over 180 kidney transplants that involved HTLV-1 either in donors or recipients, 4 out of 10 HTLV-negative recipients that became infected following transplantation of a positive donor developed HAM/TSP within 4 years. In contrast, only 1 of 59 HTLV-1 positive recipients developed complications, with the only exception being a patient who developed both TSP/HAM and ATLL at 8 and 10 years, respectively, after transplantation.^[@bibr32-2049936119868028]^

More than 35 years after the discovery of HTLV-1,^[@bibr33-2049936119868028]^ donor/recipient screening for the virus remains sporadic or nonexistent in most countries.^[@bibr34-2049936119868028]^ In 1993, the American CDC recommended that persons infected with HTLV be counseled 'not to donate blood, semen, body organs or other tissues'.^[@bibr35-2049936119868028]^ Nevertheless, in 2009 the recommendation for universal HTLV screening in deceased organ donors was dropped in the USA because of the perception of low HTLV-1 prevalence and low positive predictive value of serologic screening tests.^[@bibr36-2049936119868028]^ Alongside this recommendation, most international transplant society guidelines currently do not provide any advice on HTLV-1 screening and use of donated organs.

High rates of HTLV-1 have been found in specific groups in nonendemic regions of North America^[@bibr37-2049936119868028],[@bibr38-2049936119868028]^ and Europe,^[@bibr39-2049936119868028]^ and decades of migration/immigration and tourism/traveling have altered the demographics of many Western countries. For example, the ongoing refugee migration from the Middle East and Africa would rapidly change the prevalence of HTLV-1 in many European countries. For a while this has been the case with Latin Americans in Spain, given the large influx of immigration facilitated by strong cultural and ancestral links.^[@bibr8-2049936119868028]^ Since 1988 there has been a national register of HTLV-1 cases in Spain. As of December 2018, a total of 369 cases have been reported. Most cases are concentrated around the largest urban areas (Madrid and Barcelona), where the greatest immigrant populations are living. However, HTLV-1 infected persons have been identified across the whole Spanish geography.

In response to the worldwide evolving foci of HTLV-1 infections and the very poor prognosis of post-transplant TSP and ATLL, there are urgent calls for broader HTLV-1 screening of live and --more difficult -- deceased organ donors. Organ procurement organizations and transplant programs should determine local prevalence to guide HTLV-1 screening efforts.^[@bibr37-2049936119868028]^ Targeted screening of potential high-risk living (and deceased) donors for HTLV-1 has been recommended by some experts.^[@bibr19-2049936119868028]^ Suggestions have also been put forward for national or international registries of all HTLV-1 affected transplants.^[@bibr10-2049936119868028]^ Alerted to the dangers of rapid-onset TSP following HTLV-1 infected organ transplants, Japan begun in 2014 HTLV-1 screening of all kidney donations. Similarly, the UK issued new transplantation guidance on HTLV-1 screening of cadaveric solid organs in 2011. Finally, the Global Virus Network has recently called for more systematic HTLV-1 screening before solid organ transplantation everywhere.^[@bibr31-2049936119868028]^

It has been highlighted that 'whereas not screening donors . . . for HIV infection would be considered unethical, the same is not the case for HTLV-1, another human retrovirus, where risk assessments are made based on the predicted prevalence of cases among donors, the probable risk of transmission, and the subsequent likelihood of disease'.^[@bibr10-2049936119868028]^ Yet, those risk estimates are based on inadequate national epidemiology, ignoring changing demographics in many countries,^[@bibr1-2049936119868028],[@bibr2-2049936119868028]^ and a poor understanding of the transplant-acquired HTLV-1 disease risk.^[@bibr9-2049936119868028],[@bibr10-2049936119868028]^ The screening costs for HTLV-1 are small in comparison with the cost of post-transplant illness and/or death associated with TSP or ATLL following HTLV-1 infection.^[@bibr40-2049936119868028]^ For all these reasons, the American and European CDCs, along with other health agencies, should urgently update their policy recommendations on organ transplant HTLV-1 screening. In the meantime, some transplant centers around the world, including a few in Spain, have already implemented 'rapid' (or 'urgent') HTLV-1 testing of all deceased organ donors. In parallel, diagnostic companies should improve the specificity of HTLV-1 screening tests and design rapid tools (i.e. *point-of-care*, or PIC, tests) to minimize unwanted organ discharge.
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